相关实验视频

Updated: May 10, 2025

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source

Published on: May 29, 2021

基于PDE7A抑制剂的化学空间探索和基于机器学习的选

Yuze Li¹, Zhe Wang^1,2, Shengyao Ma¹

¹Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao 266071, China.

Pharmaceuticals (Basel, Switzerland)

|April 26, 2025

概括

研究人员确定了新型化酶7A (PDE7A) 抑制剂的关键化学结构. 这项研究选了六种有前途的化合物,用于开发神经和呼吸系统疾病的新疗法.

科学领域:

生物化学生化学
药用化学医学化学
计算化学的计算化学

背景情况:

固酶7 (PDE7) 调节循环腺单酸盐 (cAMP) 水平,影响生理功能.
PDE7A和PDE7B是不同的亚型,PDE7A抑制剂显示神经和呼吸系统疾病的治疗潜力.
由于没有FDA批准的PDE7A抑制剂,因此需要发现新的化合物.

研究的目的:

为了确定增强PDE7A抑制剂活性的关键化学子结构.
开发一种用于新型PDE7A抑制剂的预测机器学习模型.
选潜在的PDE7A抑制剂候选药物.

主要方法:

一个精心策划的化合物数据库的化学信息学分析.
可解释的机器学习来识别活性基结构 (硫胺,乙胺,).
随机森林-摩根模式模型用于预测PDE7A抑制剂.

主要成果:

从SPECS库中确定了六种具有潜在PDE7A抑制活性的化合物.
这些化合物具有有利的分子特性和强大的结合亲和力.
阐明了显著提高PDE7A抑制剂活性的关键基底结构.

结论:

这项研究推动了创新的PDE7A抑制剂的发现.
已识别的化合物显示出进一步药物开发的前景.
为未来的PDE抑制剂研究提供了宝贵的见解.

关键词:

这就是 SHAP SHAP 的意思.化学信息学化学信息学机器学习是机器学习.固酶7A抑制剂的使用虚拟选虚拟选虚拟选

更多相关视频

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

NMR-Based Fragment Screening in a Minimum Sample but Maximum Automation Mode

Published on: June 4, 2021

相关概念视频

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...